Journal
DRUG INFORMATION JOURNAL
Volume 40, Issue 4, Pages 451-461Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/216847900604000411
Keywords
dose-response; adaptive; Bayesian; frequentist
Ask authors/readers for more resources
Insufficient exploration of the dose-response is a shortcoming of clinical drug development, and failure to characterize dosing early is often cited as a key contributor to the high late-stage attrition rate currently faced by the industry. Adaptive methods, for example, make it feasible to design a proof-of-concept study as an adaptive dose-response trial. Efficient learning about the dose response earlier in development will ultimately reduce overall costs and provide better information on dose in the filing package. This article presents the Pharmaceutical Research and Manufacturers of America working group's main recommendations regarding adaptive dose-response studies. As background, traditional fixed and adaptive dose-response design's are briefly reviewed. Information on developing a Bayesian adaptive dose design and some monitoring and processing issues are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available